Posted on June 19th, 2018 by Christy J. Wilson in Pharma R&D
Modern technology seems downright magical at times. There are so many things that it can do for us at the push of a button, whether it’s our personal devices instantly retrieving information or massive industrial machines assembling our automobiles. In the 21st century, robots offer care to the sick and elderly, iPads take our orders and self-driving cars are becoming a reality. So, not surprisingly, many people can’t help but wonder why, in this age of transformative technology, that our tech isn’t also solving major health problems like cancer.
It’s not for lack of trying. Advances in artificial intelligence and artificial intelligence have many players in medicine, health care and pharma getting very excited about the potential of AI to develop innovative new treatments. Some companies are already employing machine learning to help accelerate the drug discovery process. But curing cancer? Machine learning has a lot of potential, but it also has its limits.
As Michael Kaplun, VP of Digital Solutions at Elsevier, explains in a new article in BioIT World, machines can do amazing things, but they can’t cure cancer on their own. The real hope is that, as AI technology develops further, machines will “augment” the expertise of scientists, rather than replace them—machine learning and humans working together for the betterment of mankind.
In Kaplun’s article, learn more about the reasons that AI can’t tackle disease alone, why IBM’s Watson failed to create an oncology expert advisor and what it looks like for AI to empower humans in the quest to end cancer.
Read the article here
All opinions shared in this post are the author’s own.
R&D Solutions for Pharma & Life Sciences
We’re happy to discuss your needs and show you how Elsevier’s Solution can help.
